Among individuals who were prescribed approved biologics for neuromyelitis optica spectrum disorder, those on inebilizumab had significantly higher medication adherence, according to a study presented at ECTRIMS 2024.
“The research aimed to evaluate adherence to approved biologics among patients with neuromyelitis optica spectrum disorder (NMOSD) in the U.S.,” Kristina Patterson, senior medical director of medical affairs at Amgen and co-author of the study, told Healio in an email. “NMOSD patients are at risk of life-altering relapses and hospitalizations, so treatment